EPO Patents = 2

Forward Citations = 32

Loading Chart...

2 inventors (with patents filed for the assignee):

Jon Amund Eriksen (5 out of 17 patents)

Gustav Gaudernack (1 out of 21 patents)

5 patents: Sort by Forward Citations

1. 10596239 - Peptide mixture (2020-03-24),

2. 10456457 - Peptide mixture (2019-10-29),

3. 10335473 - Peptide mixture (2019-07-02),

4. 9775892 - Peptide mixture (2017-10-03),

5. 9757439 - Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent (2017-09-12),

Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. The company focuses on oncolytic viruses, cancer vaccines, and immune modulating therapies to drive the immune system to recognize and destroy tumors. Targovax aims to improve patient outcomes by combining innovative science with a patient-centric approach.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

5 Patents

#92 in Oslo

#311 in Norway

Oslo, Norway

Targovax Asa

Forward Citations = 32

2 inventors:

Jon Amund Eriksen (5 out of 17 patents)

Gustav Gaudernack (1 out of 21 patents)

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com